PDE4A and chronic obstructive pulmonary disease: Human PDE4 inhibitors are also approved for human use (32); roflumilast is used to treat chronic obstructive pulmonary disease (33), and apremilast is used to treat psoriatic arthritis and plaque psoriasis (34).